Skip to main content

Table 1 Baseline characteristics of the study patients

From: Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients

Characteristics  
Age of recipient, years Median: 46.5 (range: 20–74)
Gender (male) N (%) 57 (66%)
Type of transplant N (%)
 Kidney 82 (95.4%)
 Kidney + pancreas 4 (4.6%)
Type of donor N (%)
 Living 8 (9.3%)
 Deceased 78 (90.7%)
Pretransplant donor (D)/recipient (R) CMV serostatus N (%)
 D+/R- 18 (20.9%)
 D−/R- 1 (1.1%)
 D−/R+ 8 (9.4%)
 D+/R+ 59 (68.6%)
Induction therapy N (%)
 Thymoglobulin 7 (8.1%)
 Basiliximab 62 (72.1%)
 None 17 (19.8%)
Maintenance immunosuppression N (%)
 Tacrolimus +mycophenolate mofetil + prednisone 77 (89.5%)
 Tacrolimus + mycophenolate sodium + prednisone 7 (8.1%)
 Cyclosprine A + mycophenolate mofetil + prednisone 1 (1.2%)
 Tacrolimus + everolimus + prednisone 1 (1.2%)
The time of VGCV initiation (days), mean ± SD [range] 9 ± 4.7 [0–25]
The time of VGCV discontinuation (days), mean ± SD [range] 92.4 ± 13.1 [53–122]
Duration of antiviral prophylaxis (days), mean ± SD [range] 83.1 ± 13.4 [40–113]
Tacrolimus concentration (ng/mL), mean ± SD [range]
 Day 30 10.4 ± 3.7 [0.3–23]
 Day 90 9.5 ± 4.5 [0.3–25.2]
 Day 360 7.4 ± 2.8 [3.2–22.4]
Allograft function (eGFR; mL/min/1.73 m2), mean ± SD [range]
 Day 30 48.7 ± 21.9 [6.7–103.7]
 Day 90 50.4 ± 21.0 [8.5–98.9]
 Day 360 51.3 ± 20.4 [10.2–96.7]
  1. VGCV valganciclovir, eGFR estimated glomerular filtration rate